Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance
Frontiers in Pharmacology · 29.04.2026 · 17
DOI: 10.3389/fphar.2026.1805842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.04.2026. Verfasst von Alessia Zinzi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The spread of counterfeit drugs represents a serious threat to public health because they may be ineffective or cause the onset of severe suspected adverse drug reactions (ADRs). To date, the traceability of semaglutide-based products, widely used off-label for weight loss, is not a well-studied area.
Methods
The aim of this study was to perform a descriptive analysis to explore and describe the characteristics of safety cases related to potential counterfeit semaglutide products by using the European pharmacovigilance database EudraVigilance. Individual Case Safety Reports (ICSRs) were retrieved over the period from 1 January 2018 to 31 December 2025.
Results
A total of 234 Individual Case Safety Reports (ICSRs) related to potential counterfeit semaglutide were retrieved from EudraVigilance, of which N = 172 (73.5%) were related to females and N = 83 (35.5%) to adult patients. A total of 89.3% of all suspected ADRs were serious. The most frequently reported suspected ADRs were “vomiting”, “nausea”, and “hypoglycemia”. The analysis of disproportionality showed a higher reporting frequency of “hypoglycemia”, “product use in unapproved indication”, “malaise”, and “drug ineffective” with potential counterfeit semaglutide compared to non-counterfeit semaglutide.
Discussion
The present pharmacovigilance study showed a useful role in identifying potential counterfeit medicine suspected ADRs. Further studies are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy.
- Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.
- Department of Experimental Medicine - Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Naples, Italy.
Zitieren
APA
Zinzi, A., Gaio, M., Ruggiero, R., Mascolo, A., Riemma, M. A., Cipriani, M., Laino, L. V., Berrino, L., Rossi, F., & Capuano, A. (2026). Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1805842
Vancouver
Zinzi A, Gaio M, Ruggiero R, Mascolo A, Riemma MA, Cipriani M, et al. Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1805842
BibTeX
@article{Zinzi2026,
author = {Zinzi, Alessia and Gaio, Mario and Ruggiero, Rosanna and Mascolo, Annamaria and Riemma, Maria Antonietta and Cipriani, Mattia and Laino, Ludovica Vittoria and Berrino, Liberato and Rossi, Francesco and Capuano, Annalisa},
title = {Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1805842}
}
EUVIMED